Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 04, 2015 3:34 AM ET

Healthcare Providers and Services

Company Overview of 23andMe, Inc.

Company Overview

23andMe, Inc. operates as a personal genetics company that provides ancestry-related genetic reports and uninterpreted raw genetic data. The company helps individuals understand their own genetic information through DNA analysis technologies and Web-based interactive tools. Its Personal Genome Service enables individuals to gain deeper insights into their ancestry and inherited traits. The company was founded in 2006 and is based in Mountain View, California.

1390 Shorebird Way

Mountain View, CA 94043

United States

Founded in 2006

Phone:

650-938-6300

Fax:

650-938-6305

Key Executives for 23andMe, Inc.

Co-Founder, Chief Executive Officer and Director
President and Director
Age: 47
Chief Science Officer and Head of Therapeutics
Age: 61
Chief Medical Officer
Chief Legal and Regulatory Officer
Age: 50
Compensation as of Fiscal Year 2014.

23andMe, Inc. Key Developments

23andMe, Inc. Appoints Robert Gentleman as Vice President of Computational Biology

23andMe, Inc. announced the appointment of Robert Gentleman, Ph.D., as vice president of computational biology. Dr. Gentleman joins 23andMe to focus on the exploration of how the human genetic and trait data in the 23andMe database can be used to identify new therapies for disease. Most recently, Dr. Gentleman served as senior director of bioinformatics and computational biology at Genentech. In addition to broadly overseeing computational biology activities at the company, Dr. Gentleman will specifically focus on collaborating with Dr. Richard Scheller, 23andMe chief science officer and head of therapeutics. He will work with Dr. Scheller and others to help the newly formed therapeutics group utilize data analytics and theoretical models to identify trends and ultimately advance the drug research and discovery process.

23andMe Appoints Erynn Gordon as Medical Marketing Director

23andMe announced the appointment of Erynn Gordon, MS, CGC as medical marketing director. Gordon is a board certified genetic counselor with more than 14 years of clinical and research experience in genetics. Gordon has also served as president of the American Board of Genetic Counseling (ABGC), chair of the ethics advisory board of the National Society of Genetic Counselors (NSGC) and is currently serving as vice chair of the New Jersey Board of Medical Examiners' Genetic Counseling Advisory Committee. In her role at the company, Gordon will oversee engagement with the medical community, as well as strategic initiatives at the company's related to clinical applications. In this capacity, Gordon joins the newly created commercial marketing group led by Ruby Gadelrab, vice president of commercial marketing. Gordon will also work closely with company's chief medical officer, Jill Hagenkord, MD and her medical affairs team. Both Gadelrab and Hagenkord are leading company's efforts to engage the medical and scientific communities. Before joining the company, Gordon was a lead genetic counselor and medical liaison on the commercial team at Invitae.

23andMe Appoints Richard Scheller as Chief Science Officer and Head of Therapeutics

23andMe announced the creation of a new therapeutics group and appointment of Richard Scheller, Ph.D. as chief science officer and head of therapeutics to lead it. Dr. Scheller retired in December 2014 from a distinguished 14 year career as an executive at Genentech where he was the executive vice president of research and early development. When Dr. Scheller assumes his post at the beginning of April 2015 as 23andMe's chief science officer and head of therapeutics, he will help build a dedicated research and development team. Dr. Scheller is a member of the American Academy of Arts & Sciences and the National Academy of Sciences. He also currently serves on the Board of Trustees for the California Institute of Technology.

Similar Private Companies By Industry

Company Name Region
Aggamin Pharmaceuticals, LLC United States
Centra Health, Inc. United States
Better Health Technologies, LLC United States
Santa Rosa Consulting, Inc. United States
Specialty Surgical Center of Beverly Hills, Brighton Way United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 22, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 23andMe, Inc., please visit www.23andme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.